Cocrystal Cost Of Revenue from 2010 to 2024
| COCP Stock | USD 2.07 0.04 1.90% |
Cost Of Revenue | First Reported 2007-09-30 | Previous Quarter 35 K | Current Value 33 K | Quarterly Volatility 1 M |
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.6. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
Cocrystal | Cost Of Revenue |
Latest Cocrystal Pharma's Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of Cocrystal Pharma over the last few years. Cost of Revenue is found on Cocrystal Pharma income statement and represents the costs associated with goods and services Cocrystal Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Cocrystal Pharma's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
Cocrystal Cost Of Revenue Regression Statistics
| Arithmetic Mean | 3,398,861 | |
| Geometric Mean | 179,279 | |
| Coefficient Of Variation | 173.13 | |
| Mean Deviation | 4,814,631 | |
| Median | 201,000 | |
| Standard Deviation | 5,884,527 | |
| Sample Variance | 34.6T | |
| Range | 15.9M | |
| R-Value | 0.28 | |
| Mean Square Error | 34.4T | |
| R-Squared | 0.08 | |
| Significance | 0.31 | |
| Slope | 368,351 | |
| Total Sum of Squares | 484.8T |
Cocrystal Cost Of Revenue History
About Cocrystal Pharma Financial Statements
Cocrystal Pharma shareholders use historical fundamental indicators, such as Cost Of Revenue, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 15.2 M | 15.9 M |
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cocrystal Stock
| 0.68 | EYEN | Eyenovia | PairCorr |
| 0.53 | ENVB | Enveric Biosciences | PairCorr |
| 0.52 | A | Agilent Technologies | PairCorr |
| 0.48 | FATE | Fate Therapeutics | PairCorr |
| 0.47 | VRPX | Virpax Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.